期刊文献+

锡类散与美沙拉嗪肠溶片保留灌肠治疗溃疡性结肠炎的疗效对比 被引量:4

下载PDF
导出
摘要 目的探讨锡类散与美沙拉嗪肠溶片保留灌肠治疗溃疡性结肠炎的疗效。方法收集医院消化内科近3年共80例溃疡性结肠炎患者作为研究对象。按随机数字表法分为研究组和对照组各40例,2组基础治疗方法均相同,研究组给予锡类散灌肠,对照组给予美沙拉嗪肠灌肠。比较2组治疗前及治疗后Sutherland DAI(疾病活动指数)评分;治疗前及治疗后C反应蛋白、血红蛋白变化情况、治疗有效率及不良反应。结果 2组治疗后Sutherland DAI评分、C反应蛋白、血红蛋白、血白细胞较治疗前比较,差异有统计学意义(P>0.05);研究组总有效率较对照组比较差异无统计学意义(P>0.05);研究组不良反应发生率7.5%明显低于对照组的15.0%,差异有统计学意义(P<0.05)。结论本研究认为锡类散与美沙拉嗪肠溶片保留灌肠治疗溃疡性结肠炎疗效相近,但锡类散不良反应更少。
出处 《临床合理用药杂志》 2015年第23期66-67,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献4

二级参考文献58

  • 1潘国宗 刘彤华 见:潘国宗 曹世植9. 主编.溃疡性结肠炎[A].见:潘国宗,曹世植9.,主编.现代胃肠病学.第Ⅰ版[C].北京:科学出版社,1994.1246-1247.
  • 2潘国宗 刘彤华.Crohn病[A].见:潘国宗 曹世植 主编.现代胃肠病学[C].北京:科学出版社,1994.1154.
  • 3Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med, 1997, 337: 1029-1035.
  • 4Hanaucr SB, Feagan BG, Lichtenstein GR, Mayer LF,Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC,Olson A, Bao W, Rutgeerts P; ACCENT I Study Group.Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 359: 1541-1549.
  • 5Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med, 1999, 340: 1398-1405.
  • 6Rutgeerts P, Sandborn W J, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2005,353: 2462-2476.
  • 7Baert F, Noman M, Vermeire S, van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med, 2003, 348: 601-608.
  • 8Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG,Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology, 2001, 121: 1088-1094.
  • 9Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M,Thomsen OO, Innes A; CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology, 9005, 199: 807-818.
  • 10Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H,Raedler A, Hahn EG, Krummenerl T, Steinmann G, German ICAM-1 Study Group. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology, 2001, 120: 1339-1346.

共引文献1090

同被引文献30

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部